Aldosterone synthase inhibitor ( BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind, placebo‐controlled, Phase I trial
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15518 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Stefan R Bornstein und 8 weiteren Autor:innen. Beteiligte Einrichtung: Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Albuminuria. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boehringer Ingelheim.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
This Phase I study evaluated the safety and early efficacy of an aldosterone synthase inhibitor (BI 690517) in people with diabetes and albuminuric chronic kidney disease.
Methods
Double‐blind, placebo‐controlled study (NCT03165240) at 40 sites across Europe. Eligible participants [estimated glomerular filtration rate ≥20 and
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany.
- Department of Clinical Pharmacy and Pharmacology University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
- Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany.
- Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, USA.
- Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
- Providence Health Care, University of Washington, Spokane, Washington, USA.
ORCID-Profile: Dick de Zeeuw, Hiddo J L Heerspink, Friedrich Schulze, Katherine R Tuttle, Samy Hadjadj, Peter Rossing
Förderung
- Boehringer Ingelheim
Zitieren
APA
Bornstein, S. R., de Zeeuw, D., Heerspink, H. J. L., Schulze, F., Cronin, L., Wenz, A., Tuttle, K. R., Hadjadj, S., & Rossing, P. (2024). Aldosterone synthase inhibitor ( BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind, placebo‐controlled, Phase I trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15518
Vancouver
Bornstein SR, de Zeeuw D, Heerspink HJL, Schulze F, Cronin L, Wenz A, et al. Aldosterone synthase inhibitor ( BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind, placebo‐controlled, Phase I trial. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15518
BibTeX
@article{Bornstein2024,
author = {Bornstein, Stefan R and de Zeeuw, Dick and Heerspink, Hiddo J L and Schulze, Friedrich and Cronin, Lisa and Wenz, Arne and Tuttle, Katherine R and Hadjadj, Samy and Rossing, Peter},
title = {Aldosterone synthase inhibitor ( BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind, placebo‐controlled, Phase I trial},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15518}
}
EUVIMED